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Abstract 
Background: Lung cancer is the leading cause of cancer-related deaths worldwide. 25% show 
neuroendocrine differentiation (typical/atypical carcinoids, large-/small-cell neuroendocrine 
carcinomas). Carcinoids present with long survival rates, but metastatic carcinoids correlate with 
decreased survival and are commonly insensitive to standard chemotherapy or radiation. 
Therefore, novel therapeutic strategies are urgently needed.  
Material and methods: 70 representative tumor specimens were used for next-generation 
sequencing analysis of 14 genes related to therapy response. Additionally, mRNA-expression 
profiles of 60 matching samples were determined for 13 selected drug targets by using the 
NanoString nCounter technology.  
Results: A number of features known to sensitize tumors for different targeted therapies could be 
identified, which hopefully improve the clinical management of this subgroup of lung neoplasias. In 
particular, EGFR expression was observed in the investigated tumors in a noteworthy manner. 
Additionally, MDM2 was strongly expressed in the majority of all samples whereas the expression 
of its physiological inhibitor, CDKN2A, was nearly absent in all low-grade tumors. TP53 showed a 
high frequency of variants in high-grade tumors but mutations were rare in carcinoids.  
Conclusion: Based on our results, therapeutic approaches with MDM2-inhibitors and 
monoclonal anti-EGFR antibodies may be promising in pulmonary carcinoid tumors. 









Lung cancer is the leading cause of 
cancer-related deaths worldwide [1-3], twenty-five 
percent of these belong to the group of 
neuroendocrine tumors [4]. These tumors encompass 
small-cell lung carcinoma (SCLC), large-cell 
neuroendocrine carcinoma (LCNEC), as well as 
typical (TC) and atypical carcinoids (AC) [5]. Patients 
suffering from TC have excellent survival rates with 
87-100%, but some present with lymph-node 
metastasis (4-15%) [6-15]. Atypical carcinoids are 
more aggressive (survival rate 61-88%) and show 
higher frequency of nodal metastasis [8-14, 16]. 
According to the WHO classification from 1999, 
LCNEC was assigned to the non-small cell lung 
cancers (NSCLC) but shows similar biological 
behavior as SCLC with a five-year survival rate of 
15%-57% [4, 8]. Up to 20% of all lung cancer 
incidences are SCLC showing the poorest five-year 
survival rates with less than 5% [4, 5, 8, 15]. 
High-grade neuroendocrine carcinomas of the lung 
occur almost exclusively in older patients (median 61 
years) with a history of smoking, whereas lung 
carcinoids occur frequently in never smokers and 
younger patients (mean 45-55 years) [7, 15, 17, 18].  
Carcinoid tumors are predominantly treated 
surgically, metastatic tumors are commonly not 
sensitive to chemotherapeutic regimes or radiation [4, 
19]. Adjuvant chemo- or radiotherapy should be 
considered in completely resected AC with 
mediastinal lymph node involvement [6, 20, 21]. 
Combinations of chemotherapeutics are usually 
platinum- or streptozoticin-based [20].  
For SCLC, chemotherapy with cisplatin plus 
etoposide is a well-established treatment since these 
tumors are notably sensitive to chemo- and 
radiotherapy [4]. An optimal treatment for LCNEC is 
still under investigation due to the relative rarity of 
this entity [4]. As defined by the WHO classification 
guidelines, LCNEC belongs to NSCLC, leaving it to 
the physician whether to treat it similarly to SCLC or 
NSCLC [8]. In fact, patients receiving SCLC-based 
regimens showed a significantly better outcome [20, 
22].  
The present study was conducted to identify 
markers for personalized therapeutic concepts in 
pulmonary neuroendocrine tumors, potentially 
leading to an improved clinical management. 
MATERIAL AND METHODS 
Demographic Data and Study Design 
The study is based on a collective of seventy 
representative formalin-fixed, paraffin-embedded 
pulmonary neuroendocrine tumors (17 TC, 17 AC, 19 
LCNEC, and 17 SCLC) used for sequencing. For 
expression analysis, 60 samples were investigated (16 
TC and 13 AC, 16 LCNEC and 15 SCLC). The initial 
diagnosis was re-evaluated by two experienced 
pathologists (JWO, TMA). Specimens were taken from 
the Institute of Pathology at the University Hospital 
Essen (Germany) from 2005 till 2012. TNM-staging 
was based on the WHO Classification of Tumours 
guidelines (2004) [18]. The mean age at date of 
diagnosis was 58.6 years (median age: 59.0 years; 95% 
CI: 50.8-66.9 months). Survival data were available for 
34 patients with twenty-two reported deaths at the 
time of data collection. Patients receiving 
chemotherapy before resection were excluded. The 
study was approved by the ethical committee of the 
University Hospital Essen (ID: 13-5382-BO). The 
investigations conform to the principles outlined in 
the declaration of Helsinki. 
Sample Preparation  
Genomic DNA was isolated on a Maxwell® 16 
Research (Promega Corporation, Madison, USA) as 
recommended in the manufacturer’s protocol. RNA 
extraction was performed using the RNeasy FFPE kit 
(Qiagen, Hilden, Germany) according to the 
manufacturer’s recommendations. Nucleic acid 
quantification was performed using Qubit (Life 
Technologies, Carlsbad, USA) and Nanodrop 1000 
instrument (Thermo Fisher Scientific, Waltham, USA). 
RNA integrity was assessed using an Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, USA) 
at the NanoString nCounter Core Facility at the 
University of Heidelberg (Germany) by smear 
analysis.  
NanoString CodeSet Design and Expression 
Quantification 
Important genes for different tumor-associated 
signaling pathways were included in the Custom 
CodeSet using the Standard Chemistry. The CodeSet 
contained a total of 91 genes and 13 of these genes 
were considered as potential pharmaceutical targets 
(ALK, CDKN2A, EGFR, FAS, FGFR1, FIGF, FLT4, IGF1, 
IGF2, KDR, MDM2, MET, MTOR).  
Probe-sets for each gene were designed and 
synthesized at NanoString Technologies (Seattle, 
USA). Total RNA (100 ng) from FFPE material was 
measured at the NanoString nCounter Core Facility at 
the University of Heidelberg, Germany.  
Next-Generation Sequencing  
Sample preparation was done using the TruSeq 
Amplicon - Cancer Panel (Illumina Inc., San Diego, 
CA, USA) followed by paired-end sequencing on the 
MiSeq Personal Sequencer (Illumina) according the 
protocols provided by the manufacturer. The Cancer 




Panel covered the following 48 tumor-relevant genes 
(table 1) including 221 mutation hotspots. Library 
construction followed the TrueSeq Custom Amplicon 
– Library Preparation guide. 
FastQ-files were aligned against the Hg19 build. 
For analysis of the aligned reads including variant 
calling, the software Avadis NGS (Strand Scientific 
Intelligence, California, USA) was used. Reads with a 
quality score <30 were discarded. After removal of 
SNPs, data filtering was done by excluding variants 
with <25 effective variant reads or below 10% 
variation frequency. Synonymous variants were 
removed.  
Finally, variants were analyzed for their 
functional impact on the protein-activity by using 
MutationAssessor (release 2) [23] and implementation 
of the ANNOVAR algorithm [24], combining the tools 
SIFT [25], PolyPhen2 [26] and MutationTaster [27]. 
Statistical Analysis 
All statistical analyses were performed using the 
R statistical programming environment (v3.1.3). For 
dichotomous factors and linear vectors the Wilcoxon 
Mann-Whitney rank sum test was applied. For 
variance analysis of variables with more than two 
categories the Kruskal-Wallis test was performed. 
Correlations between linear vectors were analyzed by 
Spearman’s rank correlation test. Double 
dichotomous contingency tables were analyzed using 
Fisher’s Exact test. To test dependency of ranked 
parameters with more than two groups the Pearson’s 
Chi-squared test was used. COXPH-model was used 
to analyze overall survival (OS) and progression-free 
survival (PFS). PFS was calculated from the first day 
of chemotherapy until progression, death from any 
cause, or the last time of follow up. OS was defined as 
the time from diagnosis until the date of death or last 
follow-up. Surveillance of PFS and OS was stopped 
on August 31, 2014. Significant differences in PFS or 
OS were analyzed by the Wald-test, likelihood-ratio 
test and Score (logrank) test. 
The level of statistical significance was defined 
as p≤0.05.  
RESULTS 
Gene Expression in Pulmonary 
Neuroendocrine Tumors 
Gene expression analysis showed strong 
differences between tumors of the four different 
entities, but also within tumors of each subgroup. 
Most strikingly, EGFR gene expression is present in 
87.5% of TC, 100% of AC, 65.3% of LCNEC and in 60% 
of SCLC. Likewise, FGFR1 is expressed in 97.3% of all 
carcinoids in a noteworthy manner. Besides, 62.5% of 
LCNEC and 80% of SCLC show strong expression of 
FGFR1. MDM2 was strongly expressed in the majority 
of all samples. 81.3% of TC, 76.9% of AC, 50% of 
LCNEC and 93.4% of SCLC present gene expression 
of MDM2. CDKN2A expression was rare in all 
low-grade neuroendocrine lung tumors, but present 
in some carcinomas showing high gene expression.  
An overview of cases with increased expression 
levels is given in figure 1, an overview of all 
expression pattern is shown in table 2. 
Occurrence of Mutations in Pulmonary 
Neuroendocrine Tumors 
86 functionally deleterious variants were 
determined within 13 therapy-relevant genes in 49 out 
of 70 samples. Four of the variants could be detected 
in TC, 14 in AC, 30 in LCNEC and 38 in SCLC. 
In seven samples (10%; one TC, two AC, one 
LCNEC and three SCLC), variants in the EGFR gene 
were found, but none of them is known or predicted 
to activate the receptor. For ERBB2, a receptor tyrosine 
kinase (RTK), closely related to EGFR, three different 
variants could be observed in eleven samples.  
Activating KRAS variants downstream of these 
receptors were found in three tumors (two LCNEC 
and one AC). Additionally, one sample showed 
activating mutations in the NRAS gene locus. BRAF 
variants occurred in three samples (4%), two LCNEC 
and one SCLC. Five different variants of PIK3CA were 
found in six tumor samples.  
 
Table 1. Overview of all genes covered by the NGS cancer hotspot panel. The Panel consists of two-times 221 probes for paired-end 
sequencing covering 221 mutational hotspots in 48 genes. 
ABL1 AKT1 ALK APC ATM BRAF CDH1 CDKN2A 
CSF1R CTNNB1 EGFR ERBB2 ERBB4 FBXW7 FGFR1 FGFR2 
FGFR3 FLT3 GNA11 GNAQ GNAS HNF1A HRAS IDH1 
JAK2 JAK3 KDR KIT KRAS MET MLH1 MPL 
NOTCH1 NPM1 NRAS PDGFRA PIK3CA PTEN PTPN11 RB1 
RET SMAD4 SMARCB1 SMO SRC STK11 TP53 VHL 
 
 




Table 2. Results of the gene expression analysis. Minimum, maximum and median for all 13 therapy relevant markers in the overall cohort 
of pulmonary neuroendocrine tumours is shown. Additionally, the mean value of tumours expressing the mentioned markers as well as 
the percentage of tumours expressing these markers is shown for each entity. Besides, the number of cases showing an outstanding 





Figure 1. Percentage of tumours showing highly increased gene expression. One-third of all pulmonary neuroendocrine tumours show strong overexpression of 
EGFR and FGFR1. Of note, also one-third of tumours show high IGF2 expression and 10% present with high IGF1 expression. More than 50% of all tumours show highly 
elevated MDM2 expression. 
 
 
Interestingly, TP53 showed the highest 
frequency of variants with 31 alterations in 23 samples 
(33%), whereas the percentage was varying in the 
different neuroendocrine subtypes. 64.7% of all SCLC 
and 63.2% LCNEC showed a functional inactivation 
of P53 via TP53 mutations. No TP53 alterations were 
found in TC or in AC. 
A summary of all mutations is given in 
Supplementary table 1. 
Expression and mutation frequency are 
summarized in table 3 for each tumor entity.  
Association with Clinicopathological 
Parameters  
EGFR, FLT4 and FIGF show highly significant 
differences in their expression levels between the four 
investigated tumor entities (p=0.0044, p=0.0054 and 
p=0.0096, respectively). Elevated EGFR gene 
expression (p=0.0002) is more prominent in carcinoid 
tumors compared to carcinomas. Also FGFR1 gene 
expression presents with significant differences 
(p=0.0301). Furthermore, upregulated EGFR gene 
expression associated significantly with lower 




IASLC-Grade (p=0.0005). FGFR1 as well as FLT4 show 
highly significant associations with tumor grade 
(p=0.0025 and p=0.0061, respectively). High FIGF 
(p=0.0210, HR: 1.40) and FAS (p=0.0233, HR: 1.27) 
gene expression levels seem to be associated with 
shortened PFS. In high-grade tumors, high FIGF 
mRNA levels identified a group of poor responders to 
therapy (COXPH: p=0.0347).  
The appearance of TP53 variants was 
significantly associated with tumor type (p<0.0001) 
and is associated with carcinomas. PIK3CA shows 
variants in 5.9% of AC and 23.5% of SCLC, whereas 
TC and LCNEC present none of these variants 
(p=0.0116). Tumors infiltrating lymph nodes present 
with higher frequency of TP53 variants (p=0.0007), as 
well as ERBB2 variants (p=0.0051) or BRAF mutations 
(p=0.0468).  
PIK3CA variants are associated with shortened 
OS (p=0.0019, HR: 2.54). Activating mutations in the 
KRAS gene (p=0.0003, HR: >10) are associated with a 
higher risk of progression. 
 
Table 3. Overview of results of the biomarker screening. Data for the percentage of tumours expressing each marker as well as the 
percentage of tumours showing inactivating genetic variants are shown. 
BRAF  0%  0%  11%  6% 
EGFR 88% 6% 100% 12% 56% 6% 60% 18% 
ERBB2  12%  12%  16%  24% 
FAS 63%   23%   31%   20%  
FGFR1 100% 0% 92% 6% 63% 5% 80% 0% 
FIGF 38%   0%   31%   7%  
FLT4 69%   38%   13%   20%  
HRAS   0%  0%  0%  0% 
IGF1 88%   38%   56%   53%  
IGF2 88%   85%   56%   87%  
KDR 69% 0% 54% 6% 31% 0% 40% 0% 
KIT   0%  12%  0%  0% 
KRAS   0%  6%  11%  0% 
MDM2 81%   77%   50%   93%  
MET 69% 0% 62% 12% 31% 5% 60% 0% 
MTOR 81%   100%   44%   80%  
NOTCH1   0%  0%  0%  0% 
NRAS   0%  0%  0%  6% 
PIK3CA   0%  6%  0%  24% 
RET   6%  6%  5%  18% 




Until now, studies investigating novel 
therapeutic approaches for pulmonary carcinoid 
tumors are lacking due to the rather long overall 
survival rates of patients with carcinoids. 
Nevertheless, tumors associated with a syndrome are 
resistant to chemo- and radiotherapy in most cases. 
This study is one of the first approaches to investigate 
a broad spectrum of biomarkers potentially predicting 
response to different chemotherapeutic agents. For 
mRNA expression analysis, the NanoString nCounter 
technology was used and additionally, 221 mutation 
hotspots were screened via massive parallel 
sequencing by synthesis.  
Erlotinib, gefitinib or icotinib, in second 
generation also afatinib, are epidermal growth factor 
receptor tyrosine-kinase inhibitors (EGFR-TKI) used 
for the treatment of NSCLC harboring activating 
EGFR mutations [28]. Pathway activation 
downstream of EGFR, e.g. by KRAS mutations, is 
known to be a resistance mechanism for EGFR-TKI 
therapeutic approaches, but also the appearance of 
resistance mutations within the EGFR gene (e.g. 
p.T790M) has been described [29]. Moreover, 
continued activation of PI3K signaling via mutated 
PIK3CA was identified to abrogate gefitinib-induced 
apoptosis [29]. Further studies confirmed that the 
PI3K pathway is involved in different resistance 
mechanisms with respect to EGFR therapy 
approaches [30]. Consequently, different trials using 
PI-103, a PI3K/mTOR double inhibitor, in 
combination with EGFR-TKI therapy were initiated.  
In our study, none of the tumors showed 
classical activating mutations in the EGFR gene. Of 
note, eight mutations impairing protein function were 
found in pulmonary neuroendocrine tumors 
regardless of the subtype (figure 2). A present study 
revealed that also cases with other non-classical 
mutations and complex mutational events had similar 
end-point outcomes to TKI therapy compared with 
classical activating mutations [31]. Besides, anti-EGFR 
antibody therapy with cetuximab may be a possible 
alternative. Cetuximab activity in NSCLC was found 




in tumors that expressed high levels of EGFR only 
[32], but also other monoclonal anti-EGFR antibodies 
were evaluated. These include matuzumab, 
panitumumab and most promising necitumumab, 
leading to an increased survival compared to 
cetuximab [33]. In our study, the majority of carcinoid 
tumors and more than half of all high-grade tumors 
show strongly upregulated expression levels of EGFR; 
one third of all NELC present with a highly increased 
EGFR gene expression level (figure 2). Furthermore, it 
has been reported that more than half of all carcinoids 
show increased EGFR copy numbers [34]. Thus, 
making them potential targets for monoclonal 
anti-EGFR antibodies.  
 
 
Figure 2. The plot in the upper row shows the percentage of tumours with 
EGFR variants predicted to influence protein function. Nevertheless, classical 
EGFR mutations were not found in the collective investigated. The plot at the 
bottom shows the percentage of tumours expressing EGFR. Carcinoids present 
with elevated EGFR expression compared to carcinomas. 
 
Lapatinib is currently approved for patients with 
ERBB2 (HER2)-positive metastatic breast cancer in 
combination with capecitabine after prior therapy 
with anthracycline, taxane, and trastuzumab [35, 36]. 
It is also approved in combination with letrozole in 
postmenopausal women with ERBB2-positive 
advanced breast cancer where endocrine therapy is 
indicated [36, 37]. Mutations in the ERBB2 (HER2) 
gene locus were reported in 1.5%-2% of all NSCLC, 
but this aberration occurred exclusively in 
adenocarcinomas [38, 39]. We found nine patients 
(13%) harboring the activating p.L785R and the 
p.R868W. It has been shown that patients with 
mutations and without amplification of the ERBB2 
gene locus can respond to lapatinib [36, 39]. 
Activating BRAF mutations were found in two 
LCNEC and one SCLC. Patients harboring activating 
BRAF mutations are known to be sensitive for therapy 
with vemurafenib [40]. Activation downstream of 
BRAF, primary through RAS mutations, is reported to 
act as a potential resistance mechanism [41]. RAS 
mutations were observed in all tumor entities except 
TC, but never appeared in combination with BRAF 
mutations. The response of pulmonary 
neuroendocrine tumors harboring BRAF mutations to 
vemurafenib has to be proven in further studies. 
A large part of human cancers shows TP53 
inactivation, mostly by mutations or loss of 
heterozygosity (LOH) of the whole gene locus. Even 
in TP53 wild type tumors the functional protein is 
inactivated resulting from some putative mechanisms 
of amplification and overexpression of MDM2, the 
physiological inhibitor of P53 [42-46]. MDM2 itself is 
controlled by the tumor suppressor P14/ARF 
(encoded by the gene locus of CDKN2A). Numerous 
environmental influences and genetic alterations 
induced by platin compounds are able to activate P53 
by post-translational modifications, which results in 
cell cycle arrest, cellular senescence, or apoptosis [47]. 
Nutlin-3A, a cis-imidazoline analogue, is a potent and 
selective MDM2 inhibitor [48, 49] that prevents 
MDM2-TP53-interaction by binding to the 
hydrophobic binding pocket of MDM2 leading to an 
immediate reactivation of P53 [48, 50, 51]. It is 
currently tested in a phase I clinical trial 
(NCT01143519, NCT00623870) [51]. 
Second-generation MDM2 inhibitors (RG7112, 
RO5045337, Idasanutlin, RG-7388, DS-3032b, 
SAR405838, CGM-097, MK8242, HDM201 etc.) are 
currently tested in phase I-III trials for various 
diseases (NCT01877382, NCT02319369, NCT00559533, 
NCT01985191, NCT02016729, NCT02343172 etc.) 
For high-grade neuroendocrine lung tumors, 
TP53 mutations were found in the majority of tumors 
(figure 3A). As described, the main alternative 
mechanism seems to be LOH, so MDM2 inhibition 
may not be successful. In contrast, carcinoids lack 
genetic alterations of TP53, but about 80% of samples 
show a dramatically high MDM2 gene expression 
level (figure 3B). Additionally, CDKN2A inhibiting 
MDM2 is absent in most pulmonary carcinoids. 
Therefore, pulmonary carcinoids seem to be an ideal 
target for Nutlin-3A therapy. A major issue with 
carcinoid tumors is the rarity of the disease and 
therefore it is difficult to conduct such studies. Also, 
there is an issue if drugs such as; everolimus could be 
administered as adjuvant therapy and for how long 




after surgery [52]. Everolimus could be used as 
treatment in the case that surgery is not possible, or 
could be used as adjuvant therapy in the case that 
surgery is not possible and only endoscopic 
debulking procedures are possible. The length of the 
therapy administration depends on multiple factors 
such as local disease progression and drug side 
effects. There are still many matters to clarify as 




Figure 3. The plot at the top is showing the percentage of tumours with 
inactivating mutations in the TP53 gene. The plot at the bottom shows the 
percentage of tumours with high MDM2 expression. MDM2 overexpression is 
one possible mechanism to avoid TP53-dependet apoptosis and cell senescence. 
 
CONCLUSION 
Carcinoids of the lung show long survival rates, 
but sometimes progress to a systemic disease. 
Carcinoids with a syndrome are resistant to chemo- 
and radiotherapy and new therapeutic approaches are 
needed. Based on our results, therapeutic approaches 
with MDM2 inhibitors and monoclonal anti-EGFR 
antibodies may be a promising novel therapeutic 
approach and need to be confirmed in further in vitro 
and in vivo studies.  
SUPPLEMENTARY MATERIAL  
Supplementary table 1.  
http://www.jcancer.org/v07p2165s1.xlsx  
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